Previous 10 | Next 10 |
LeMaitre has been beaten down lately, however, the pullback lends significant opportunity to add to a long-term compounder. The company has a differentiated value proposition from an investment perspective and operates within a niche segment. We've priced LMAT at $52 per share on ...
BURLINGTON, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Sidoti Summer Small Cap Virtual Conference on Wednesday, June 15, 2022, at 2:30 PM ET. LeMaitre is a provider of devices, impla...
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend Champion, Contender, An...
The following slide deck was published by LeMaitre Vascular, Inc. in conjunction with this event. For further details see: LeMaitre Vascular (LMAT) Investor presentations - Slideshow
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend Champion, Contender, An...
LeMaitre Vascular, Inc. (LMAT) Q1 2022 Earnings Conference Call April 28, 2022 17:00 ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer Dave Roberts - President Conference Call Participants Zach Weiner - Jefferies Brooks O&...
LeMaitre (LMAT) -4% on reporting Q2 EPS of $0.27 missing consensus by 1 cent. Sales of $39.6M, +10% was driven by Artegraft, XenoSure, carotid shunts, allografts and valvulotomes. By geography, sales were driven by the Americas (+12%), EMEA (+6%) and APAC (+9%). Gross margin decline...
LeMaitre Vascular press release (NASDAQ:LMAT): Q1 GAAP EPS of $0.27 misses by $0.01. Revenue of $39.56M (+10.3% Y/Y) beats by $0.91M. Q2 2022 Guidance - Sales of $40.1M - $42.1M 2022 Full Year Guidance - Sales of $160.0M - $164.0.M vs. consensus estimate of $164.73M For further details...
BURLINGTON, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2022 results, announced a $0.125/share quarterly dividend and provided guidance. Q1 2022 Financial Results Sales of $39...
BURLINGTON, Mass., April 15, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2022 financial results on Thursday, April 28, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same ...
News, Short Squeeze, Breakout and More Instantly...
LeMaitre Vascular Inc. Company Name:
LMAT Stock Symbol:
NASDAQ Market:
LeMaitre Vascular Inc. Website:
2024-06-23 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-01 09:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BURLINGTON, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00 AM ET at the Marriott Marquis in New York City...